Heart failure pharmacotherapy

Ng TMH, Carter O, Guillory GS, et al. High-impact articles related to the pharmacotherapeutic management of systolic heart failure. Pharmacotherapy 2004 24 1594-1633. 

Luzier AB, DiTusa L. Underutilization of ACE inhibitors in heart failure. Pharmacotherapy. 1999 19 1296-1307. 

Chow MSS, Scheife RT, eds. Therapeutic and research strategies for congestive heart failure. Pharmacotherapy 1993 13 (5 pt 2) 71S-99. 

Patterson JH. Angiotensin II receptor blockers in heart failure. Pharmacotherapy 2003 23 173-182. 

Nawarskas JJ, Spinier SA. Does aspirin interfere with therapeutic efficacy of angiotensin-converting enzyme inhibitors in hypertension or congestive heart failure Pharmacotherapy 1998 18 1041-1052. 

Reddy P, Dunn AB. The effect of beta-blockers on health-related quality of life in patients with heart failure. Pharmacotherapy 2000 20 679-89. 

MungerMA, Cheang Kl Beta-blocker therapy A standard of care for heart failure. Pharmacotherapy... 

Cavallari LH, Groo VL, Viana MA, Dai Y, Patel SR, Stamos TD. Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure. Pharmacotherapy 2010 30(1) 1-9. 

From Parker RB, Patterson JH, Johnson JA. Heart failure. In DiPiro JT, Talbert RL, Yee CC, et al, (eds.) Pharmacotherapy A Pathophysiologic Approach. 6th ed. New York McGraw-Hill 2005 220, with permission. 

To determine the efficacy of nonpharmacologic and pharmacotherapy for both STE and NSTE ACS, monitor patients for (1) relief of ischemic discomfort (2) return of ECG changes to baseline and (3) absence or resolution of heart failure signs. 

FIGURE 6-6. Decision algorithm for long-term ventricular rate control with oral drug therapy for patients with paroxysmal or permanent atrial fibrillation, bpm, beats per minute CCB, calcium channel blocker (diltiazem or verapamil) HF, heart failure LV, left ventricular function LVEF, left ventricular ejection fraction. (Algorithm adapted with permission from Tisdale JE, Moser LR. Tachyarrhythmias. In Mueller BA, Bertch KE, Dunsworth TS, et al. (eds.) Pharmacotherapy Self-Assessment Program, 4th ed. Kansas City American College of Clinical Pharmacy 2001 ... 

These population changes have important implications for pharmacotherapy. It is now widely accepted that genetic differences between the various ethnic groups are quite small and probably less than individual differences. The recent experience with the newly approved congestive heart failure medication, BiDil, suggests that even minor differences can have significant pharmacological consequences. 

Pharmacotherapy that has been proven to decrease mortality, heart failure, reinfarction, or stroke should be started before hospital discharge for secondary prevention. 

Page II RL, Gozansky WS, Ruscin JM. Possible heart failure exacerbation associated with rosiglitazone case report and literature review. Pharmacotherapy 2003 23 945-54. 

RoccoTP, Fang JC. Pharmacotherapy of congestive heart failure. In Brunton LL, ed. The Pharmacological Basis of Therapeutics. 11th ed. New York McGraw-Hill 2006. 

The book is comprised of five sections with part I covering systemic and endoluminal therapy with an incisive overview of hemostasis and thrombosis part II covers local therapy with several chapters devoted to drug-eluting stents and restenosis therapies part III covers cell therapy and therapeutic angiogenesis and includes chapters on cell transplantation and clinical trials in cellular therapy part IV covers adjunctive pharmacotherapy with chapters devoted to various patient populations including those with heart failure, diabetes, atrial fibrillation, peripheral artery disease,... 

Herbs have been used as medical treatments since the beginning of civilization and some herbal derivatives (e.g., aspirin, reserpine, and digitalis) have become a mainstay of human pharmacotherapy. For cardiovascular diseases, herbal treatments have been used in patients with congestive heart failure, systolic hypertension, angina pectoris, atherosclerosis, cerebral insufficiency, venous insufficiency, and arrhythmia. Scientific validation of several plant species has proved the efficacy of the botanicals in reducing the... 

Munger MA, Stanek EJ. Heart failure. In Carter B, Angaran D, Sisca T, eds. Pharmacotherapy self-assessment program, 1st edition. Kansas City American College of Clinical Pharmacy, 1991 85-99. 

D. A. Sica, Pharmacotherapy in congestive heart failure drug absorption in the management of congestive heart failure loop diuretics. Congestive Heart Failure 9 287-292 (2003). 

---